Host Modulation Through Next-Generation Oral Probiotics: Can Targeted Microbiome Modulation Reverse the Inflammatory State in Periodontitis? A Narrative Review

Periodontitis is driven less by bacterial load than by a dysbiotic subgingival microbiome acting alongside a dysregulated host response, which together destroy connective tissue and alveolar bone. This understanding has shifted attention to next-generation oral probiotics as a way to target both the microbial and inflammatory components of disease. This narrative review evaluates current evidence on next-generation oral probiotics as a precision approach to periodontal microbiome modulation, their influence on host inflammatory responses and periodontal homeostasis, and their potential to resolve dysregulated inflammation and improve clinical outcomes. We searched PubMed and Google Scholar for systematic reviews, narrative reviews, randomized clinical trials, and observational and experimental studies published between 2021 and 2026. Probiotic supplementation, particularly when combined with conventional therapy such as scaling and root planing, has shown potential to reduce periodontal inflammation and improve selected clinical parameters. Probiotics have been associated with changes in pro-inflammatory mediators, including interleukin (IL)-1β, IL-6, and tumor necrosis factor-alpha (TNF-α), and matrix metalloproteinases, while potentially promoting anti-inflammatory mechanisms involving IL-10 and the resolution of inflammation; additional effects may include modulation of oxidative stress, improved epithelial barrier function, and indirect regulation of osteoclast-mediated alveolar bone remodeling. Current evidence nonetheless remains heterogeneous in strain, dose, and protocol, with mostly short follow-up, so probiotics are best regarded as a promising adjunct that attenuates inflammation and enhances conventional therapy rather than an independent means of reversing established periodontitis. Standardized, strain-specific protocols and adequately powered long-term trials are needed.